# 外周支架市场 > 外周支架市场研究报告按材料（金属支架、生物可降解支架、高分子支架、混合支架）、按类型（药物洗脱支架、裸金属支架、覆盖支架）、按应用（外周动脉疾病、冠状动脉疾病、胆道梗阻、输尿管梗阻）、按最终用途（医院、门诊手术中心、专科诊所）及按地区（北美、欧洲、南美、亚太、中东和非洲）- 预测至2035年 - **Forecast Period:** 2025 - 2035 - **CAGR:** 3.14% - **2024:** $ 11.43 Billion - **2025:** $ 11.79 Billion - **2035:** $ 16.07 Billion - **Key Players:** Medtronic (US), Boston Scientific (US), Abbott (US), B. Braun (DE), Terumo (JP), Cook Medical (US), Cardinal Health (US), Johnson & Johnson (US), AngioDynamics (US) **Report ID:** MRFR/HC/37276-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** September 17, 2026 **URL:** https://www.marketresearchfuture.com/reports/peripheral-stent-market-39271 --- ## Market Summary ## **Peripheral Stent Market Overview** As per MRFR analysis, the Peripheral Stent Market Size was estimated at 11.43 (USD Billion) in 2024. The Peripheral Stent Market Industry is expected to grow from 11.79 (USD Billion) in 2025 to 15.58 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 3.14% during the forecast period (2025 - 2034).. ### **Key Peripheral Stent Market Trends Highlighted** The peripheral stent market is witnessing a significant growth driven by the rising prevalence of peripheral artery diseases, increasing geriatric population, and advancements in stent technology. Technological innovations, such as drug-eluting stents and bioresorbable stents, are enhancing procedural outcomes and driving demand. Improved healthcare infrastructure and a growing emphasis on minimally invasive procedures are also contributing to market expansion. The increasing awareness about cardiovascular health and lifestyle changes further underscores the need for effective treatments in this domain. Emerging markets present substantial opportunities for the peripheral stent market, particularly as healthcare access improves in regions like Asia-Pacific and Latin America.The rise in disposable incomes, along with government initiatives to enhance healthcare delivery, are expected to drive the adoption of peripheral stents. Companies can also explore partnerships with healthcare providers to develop tailored solutions for specific patient needs. Moreover, advancements in imaging and navigation technology are expected to improve intervention outcomes, creating pathways for new product development. Recent trends indicate a shift towards personalized medicine, with a focus on customizing stent designs and treatment plans based on patient-specific characteristics. There is also a growing preference for stents that can reduce the risk of restenosis, enhancing long-term efficacy.Additionally, the integration of digital health technologies, such as remote monitoring and telemedicine, is playing a crucial role in improving patient management. These trends suggest a dynamic market landscape where continuous innovation and patient-centric approaches will shape the future of the peripheral stent market. The focus is on improving device performance, achieving better patient outcomes, and expanding the scope of treatment options available to healthcare providers and patients alike. Source Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Peripheral Stent Market Drivers** ### Growing Prevalence of Peripheral Vascular Diseases The increasing incidence of peripheral vascular diseases (PVDs) is a significant driver for the Peripheral Stent Market Industry. With an aging population and an increase in lifestyle-related health issues, the demand for effective vascular interventions has risen sharply. Patients suffering from conditions such as atherosclerosis, deep vein thrombosis, and critical limb ischemia require innovative treatment options, including peripheral stenting. Peripheral vascular disease (PVD) prevalence also creates a market for peripheral stents as healthcare providers aim to enhance patient outcomes and minimize the chances of complications related to this condition. The paradigm shifts further emphasize sophisticated minimally invasive modalities that accelerate recovery and shorten hospitalization periods. This trend fosters the use of peripheral stents hence impacting the growth of the market. Furthermore, improved awareness and diagnosis rates of these diseases contribute to an increased patient pool, which further escalates the demand for stenting solutions.In addition, the educational initiatives undertaken by healthcare institutions regarding the early detection and management of PVDs support an increase in interventions. Implementing advanced technologies in stent design and material science ensures that stents are more efficient, durable, and biocompatible, meeting the specific needs of PVD patients. This evolution within the Peripheral Stent Market Industry highlights a robust growth trajectory bolstered by rising disease prevalence. ### Technological Advancements in Stent Design The Peripheral Stent Market Industry is witnessing substantial growth due to significant advancements in stent technology. Innovations such as drug-eluting stents, bioabsorbable stents and improved delivery systems are enhancing the efficacy and safety of stenting procedures. These technological advancements lead to superior patient outcomes, which, in turn, boosts the adoption rate among healthcare providers and patients alike. The continuous improvement of stent materials and designs reduces complications such as restenosis and enhances the overall treatment experience for patients suffering from vascular diseases. ### Increasing Healthcare Expenditure and Investment Increasing healthcare spending in both developed and emerging markets is another vital driver for the Peripheral Stent Market Industry. Governments and private sectors are investing significantly in healthcare infrastructure, facilitating access to advanced treatment options for patients. This commitment leads to the acquisition of state-of-the-art medical devices, including peripheral stents, thus promoting their use in clinical settings. Additionally, rising demand for quality healthcare services and improvement of patient care systems inspire investments in innovative stenting solutions, further propelling market growth. ## **Peripheral Stent Market Segment Insights** ### **Peripheral Stent Market Material Insights** The Peripheral Stent Market, focusing on the Material segment, reflects an evolving landscape with significant contributions from various types of stents. In 2023, the overall market valuation highlights the pivotal role of different stent materials, which are essential for enabling effective treatments of peripheral vascular diseases. Within this framework, Metallic Stents stand out as a key player, commanding a market value of 5.0 USD Billion in 2023 and projecting growth to a value of 6.5 USD Billion by 2032. This strong position is attributed to their durability and excellent mechanical properties, making them the preferred choice in many clinical scenarios. Biodegradable Stents are also gaining momentum, valued at 3.0 USD Billion in 2023 and expected to increase to 4.0 USD Billion by 2032, reflecting a growing trend towards stents that dissolve over time, minimizing long-term complications and promoting arterial healing. Polymeric Stents, although relatively new to the market, have begun to establish their significance, starting with a valuation of 1.75 USD Billion in 2023 and moving to 2.25 USD Billion by 2032. Their biocompatibility and flexibility appeal to specific patient needs, showing a steady increase in adoption among healthcare providers. Additionally, Hybrid Stents, which combine various materials to optimize treatment outcomes, hold a value of 1.0 USD Billion in 2023, projected to rise to 1.45 USD Billion by 2032. Although this segment constitutes a smaller market share, its innovative approach to combining the advantages of different materials draws interest from clinicians focusing on tailored vascular interventions. The Peripheral Stent Market segmentation illustrates that Metallic Stents dominate the scene with a majority holding, given their established track record and reliability in procedures. Biodegradable Stents are significant for the emerging demand for less permanent solutions and safety post-implantation, capturing considerable market attention. In contrast, Polymeric Stents and Hybrid Stents represent the evolving nature of stent technology, catering to niche segments and providing opportunities for growth amidst their lesser market valuation. The interplay of these materials in the market underscores the importance of innovation and patient-specific solutions in the ongoing development and future direction of the Peripheral Stent Market industry. Source Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Peripheral Stent Market Type Insights** The market segmentation is primarily categorized into Drug-Eluting Stents, Bare-Metal Stents and Covered Stents, each having its unique significance. Drug-Eluting Stents are recognized for their ability to minimize the risk of restenosis, thus presenting a major advantage in clinical applications, making them a preferred choice among healthcare providers. Bare-Metal Stents continue to dominate due to their cost-effectiveness and simplicity, appealing to a broad spectrum of patients and procedures. Covered Stents, while representing a smaller proportion of the market, play a crucial role in treating vascular complications and have been gaining attention for their specialized applications. The rise in cardiovascular diseases and the growing elderly population are key growth drivers for the Peripheral Stent Market. However, challenges such as stringent regulatory protocols and the high costs associated with advanced stent technologies remain prevalent. Consequently, there are significant opportunities for innovation and expanding product portfolios to enhance patient outcomes and capture a larger market share.The Peripheral Stent Market Statistics reflect these factors, showcasing its dynamic nature and potential trajectory. ### **Peripheral Stent Market Application Insights** A prominent segment encompasses the treatment of Peripheral Artery Disease and Coronary Artery Disease, where the demand remains significant due to the increasing prevalence of cardiovascular issues among an aging population. Biliary and Ureteral Obstruction are also crucial applications, addressing complications that can severely affect patient health and quality of life. Each of these areas demonstrates vital market growth, as they offer innovative solutions for improving blood flow and relieving obstructions. While the Peripheral Artery Disease segment generally commands a substantial share due to its prevalence, Coronary Artery Disease similarly reflects a growing requirement for effective stenting solutions. The rising incidences of lifestyle-related health issues globally further accentuate the need for effective intervention methods, driving the overall demand in the Peripheral Stent Market industry. Additionally, the ongoing advancements in stenting technologies present opportunities for enhancing patient outcomes, thus influencing the Peripheral Stent Market statistics favorably.Market growth within these application segments signifies a response to market needs for effective and reliable intervention methods. ### **Peripheral Stent Market End Use Insights** Hospitals play a crucial role in the market, as they are the primary setting for the majority of peripheral stent procedures, given their access to advanced technology and skilled medical professionals. Ambulatory surgical centers are increasingly gaining importance due to their ability to provide outpatient procedures, which aligns with the growing trend toward less invasive treatments and cost-effective solutions.Specialty clinics also contribute significantly, focusing on specific areas of vascular health, thereby enhancing patient outcomes through specialized care. The shift towards minimally invasive procedures and the increasing prevalence of vascular diseases are key drivers for the growth of these segments. Market growth is supported by advancements in stent technology and materials, which improve patient safety and outcomes, while challenges include stringent regulatory approvals and high costs associated with advanced stenting techniques. Overall, the Peripheral Stent Market revenue is expected to see notable gains in the coming years as these end-use segments evolve to meet patient needs more efficiently. ### **Peripheral Stent Market Regional Insights** The Peripheral Stent Market reveals a diverse regional segmentation, notably with North America holding a significant majority share, valued at 5.0 USD Billion in 2023 and projected to reach 6.5 USD Billion by 2032. This dominance is driven by advanced healthcare systems and high adoption rates of innovative medical technologies. Europe follows as another major region, with a valuation of 2.75 USD Billion in 2023, expected to grow to 3.5 USD Billion, supported by rising prevalence of vascular diseases and increasing investments in healthcare infrastructure.In the Asia-Pacific (APAC) region, the market was valued at 2.0 USD Billion in 2023 and is projected to rise to 2.75 USD Billion, reflecting growing awareness and demand for peripheral stenting procedures. South America represents a smaller segment at 0.75 USD Billion currently, anticipated to increase to 1.0 USD Billion, influenced by gradual economic growth and healthcare improvements. Meanwhile, the Middle East and Africa (MEA) segment is the least dominant, with values of 0.25 USD Billion in 2023, rising to 0.45 USD Billion, indicating emerging opportunities due to expanding healthcare services in developing nations.Overall, the regional insights into the Peripheral Stent Market segmentation underscore varied growth dynamics shaped by factors such as healthcare advancement, economic conditions and disease prevalence. Source Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Peripheral Stent Market Key Players and Competitive Insights** The Peripheral Stent Market is characterized by intense competition as numerous players vie for market share in this rapidly evolving industry. As the demand for minimally invasive treatment options for peripheral artery disease and other vascular conditions rises, companies in this market are striving to differentiate themselves through innovation, product offerings, and strategic partnerships. Key trends influencing the competitive landscape include advancements in technology, increasing incidences of lifestyle-related diseases, and a growing elderly population that is more susceptible to vascular ailments. Furthermore, regulatory approvals and clinical efficacy play significant roles in shaping market dynamics, with companies investing heavily in research and development to enhance their product profiles and gain competitive advantages. Merit Medical Systems has established a significant presence within the Peripheral Stent Market, leveraging its strong focus on innovation and customer-centric solutions. The company is recognized for its comprehensive portfolio of peripheral vascular interventions, which includes advanced stenting systems designed to meet diverse clinical needs. Merit Medical Systems emphasizes the quality and reliability of its products, backed by a dedication to improving patient outcomes. The company's established relationships with healthcare professionals and strong distribution channels enhance its market penetration and allow for better visibility within the healthcare landscape. By continuously investing in new technologies and expanding its product offerings, Merit Medical Systems is well-positioned to capitalize on emerging opportunities in the peripheral stent sector.Abbott Laboratories has marked its presence in the Peripheral Stent Market by focusing on technological advancements and innovative treatment solutions. The company is dedicated to developing cutting-edge stent systems that provide enhanced deliverability, greater flexibility, and improved patient outcomes. Abbott Laboratories’ strong commitment to research and development has led to the introduction of several novel products that address the evolving needs of clinicians and patients alike. Additionally, Abbott Laboratories benefits from its well-established reputation in the medical device industry, which aids in gaining the trust of healthcare providers. With a footprint and a diversified product line, Abbott Laboratories continues to play a pivotal role in shaping the competitive landscape of the peripheral stent market while aiming to enhance the standard of care for patients with vascular diseases. ### **Key Companies in the Peripheral Stent Market Include** - Merit Medical Systems - **[Abbott Laboratories](https://www.cardiovascular.abbott/us/en/hcp/products/peripheral-intervention/peripheral-stents.html)** - Zephyr Surgery - Biosensors International - R. Bard - Cardinal Health - L. Gore and Associates - SentreHEART - Cook Medical - Braun Melsungen - Terumo - Boston Scientific - Philips - Medtronic - Acandis ## Peripheral Stent Market Industry Developments - **Q2 2024: Boston Scientific Announces FDA Approval of Ranger™ Drug-Coated Balloon for Peripheral Artery Disease** Boston Scientific received FDA approval for its Ranger™ Drug-Coated Balloon, designed to treat patients with peripheral artery disease in the superficial femoral and popliteal arteries. The approval expands the company's portfolio of peripheral vascular intervention devices. - **Q2 2024: Medtronic Receives CE Mark for Onyx Frontier™ Drug-Eluting Stent System** Medtronic announced it has received CE Mark approval for its Onyx Frontier™ Drug-Eluting Stent System, which is indicated for use in peripheral vascular interventions. The approval allows Medtronic to market the device in the European Union. - **Q2 2024: BD Launches New Peripheral Vascular Stent System in Europe** BD announced the commercial launch of its new peripheral vascular stent system in select European markets. The device is designed to improve vessel patency in patients with peripheral artery disease. - **Q3 2024: Abbott Receives FDA Approval for Esprit BTK Everolimus Eluting Bioresorbable Scaffold System** Abbott received FDA approval for its Esprit BTK Everolimus Eluting Bioresorbable Scaffold System, intended for the treatment of below-the-knee peripheral artery disease. This marks a significant regulatory milestone for bioresorbable stent technology in the U.S. - **Q3 2024: Terumo Launches Ultimaster Tansei™ Drug-Eluting Stent in Japan for Peripheral Artery Disease** Terumo announced the launch of its Ultimaster Tansei™ Drug-Eluting Stent in Japan, expanding its peripheral vascular product offerings in the Japanese market. - **Q4 2024: Cook Medical Announces U.S. Launch of Zilver® PTX® Drug-Eluting Peripheral Stent** Cook Medical launched its Zilver® PTX® Drug-Eluting Peripheral Stent in the United States, following recent FDA approval. The stent is indicated for use in the treatment of peripheral artery disease in the femoropopliteal artery. - **Q4 2024: Cordis Announces Strategic Partnership with MedAlliance for Peripheral Drug-Eluting Stent Distribution** Cordis entered into a strategic partnership with MedAlliance to distribute MedAlliance's peripheral drug-eluting stent products in select global markets, aiming to expand access to advanced stent technologies. - **Q1 2025: Biotronik Receives CE Mark for Pulsar-18 T3 Peripheral Self-Expanding Stent System** Biotronik announced CE Mark approval for its Pulsar-18 T3 Peripheral Self-Expanding Stent System, enabling commercialization in the European Union for the treatment of peripheral artery disease. - **Q1 2025: Boston Scientific Launches Eluvia™ Drug-Eluting Vascular Stent in Asia-Pacific** Boston Scientific launched its Eluvia™ Drug-Eluting Vascular Stent in the Asia-Pacific region, expanding its global reach in the peripheral stent market. - **Q2 2025: Medtronic Announces FDA Approval of IN.PACT™ AV Drug-Coated Balloon for Peripheral Vascular Disease** Medtronic received FDA approval for its IN.PACT™ AV Drug-Coated Balloon, designed to treat peripheral vascular disease in arteriovenous fistulae for hemodialysis patients. - **Q2 2025: Abbott Launches New Generation Xience Skypoint™ Stent for Peripheral Artery Disease in Europe** Abbott announced the European launch of its new generation Xience Skypoint™ Stent, designed for the treatment of peripheral artery disease, following CE Mark approval. - **Q2 2025: Terumo Opens New Manufacturing Facility for Peripheral Vascular Devices in Vietnam** Terumo Corporation opened a new manufacturing facility in Vietnam dedicated to the production of peripheral vascular devices, aiming to meet growing global demand. ## **Peripheral Stent Market Segmentation Insights** ### **Peripheral Stent Market Material Outlook** - Metallic Stents - Biodegradable Stents - Polymeric Stents - Hybrid Stents ### **Peripheral Stent Market Type Outlook** - Drug-Eluting Stents - Bare-Metal Stents - Covered Stents **Peripheral Stent Market Application Outlook** - [Peripheral Artery Disease](../../../reports/peripheral-artery-disease-market-1540) - Coronary Artery Disease - Biliary Obstruction - Ureteral Obstruction ### **Peripheral Stent Market End Use Outlook** - Hospitals - Ambulatory Surgical Centers - Specialty Clinics ### **Peripheral Stent Market Regional Outlook** - North America - Europe - South America - Asia Pacific - Middle East and Africa -   -   -   -   -   - Beta Beta feature -   -   -   -   -   - Beta Beta feature ## Market Drivers ### 增加医疗支出 各地区医疗支出的上升是外周支架市场的重要驱动因素。随着政府和私营部门向医疗保健分配更多资源，先进医疗技术（包括外周支架）的可用性正在改善。这一资金的增加促进了创新支架解决方案的采用，这对于治疗如外周动脉疾病（PAD）等病症至关重要。最近的数据表明，医疗支出预计将在2025年前以约5%的年增长率增长，从而增强对先进医疗治疗的获取。这一趋势可能会促进外周支架市场的发展，因为医疗服务提供者投资于最先进的技术，以满足对有效治疗方案日益增长的需求。 ### 监管支持和批准流程 监管支持和简化的审批流程是影响外周支架市场的重要因素。监管机构越来越认识到创新支架技术的重要性，并致力于加快新设备的审批。这种支持性环境鼓励制造商投资于研发，推动先进支架设计的推出，以满足不断变化的患者需求。最近旨在减少临床试验和审批所需时间的举措可能会增强新产品的市场准入。因此，外周支架市场可能会受益于更加动态和竞争的环境，促进创新并改善患者护理。 ### 支架设计中的技术创新 支架设计的技术进步正在显著影响外周支架市场。药物洗脱支架、生物可吸收支架和先进材料等创新正在提高支架手术的有效性和安全性。这些创新不仅改善了患者的治疗效果，还降低了与传统支架相关的再狭窄这一常见并发症的风险。市场上对这些先进支架的采用激增，预计到2025年，仅药物洗脱支架细分市场就可能占据超过60%的市场份额。随着医疗服务提供者越来越倾向于这些尖端解决方案，外周支架市场预计将因技术进步而经历强劲增长。 ### 外周动脉疾病发病率上升 外周动脉疾病（PAD）的日益普遍是外周支架市场的主要驱动力。随着人口老龄化，影响全球数百万人的PAD发病率持续上升。这种情况常常导致严重并发症，迫切需要有效的治疗方案。外周支架市场有望从这一趋势中受益，因为支架植入手术通常用于恢复受影响动脉的血流。最近的估计表明，到2025年，PAD病例的数量可能超过2亿，从而加大对外周支架的需求。不断增长的患者群体凸显了对创新支架技术的需求，这些技术可以改善患者的治疗效果并降低并发症的风险，进一步推动市场增长。 ### 对微创手术的偏好日益增长 向微创手术的转变是推动外周支架市场的重要因素。患者和医疗服务提供者越来越倾向于这些技术，因为它们带来的好处，如缩短恢复时间、降低并发症风险和最小化疤痕。因此，外周支架手术的需求正在上升，预计到2025年，市场的复合年增长率将超过8%。这一趋势得到了成像技术和导管技术进步的进一步支持，这些进步提高了支架手术的精确性和有效性。因此，外周支架市场在利用这一日益增长的对非侵入性治疗选择的偏好方面处于良好位置。 ## Future Outlook 外周支架市场预计将在2024年至2035年间以3.14%的年均增长率增长，推动因素包括技术进步、血管疾病的日益普遍以及医疗支出的增加。 **New opportunities:** - 开发可生物降解的支架以改善患者的治疗效果。 到2035年，外周支架市场预计将实现强劲增长，反映出不断变化的医疗需求。 ## Segment Insights ### 按材料分类：金属支架（最大）与可生物降解支架（增长最快） 外周支架市场在不同材料细分中显示出明显的分布，其中金属支架作为最大的细分市场占据主导地位。由于其成熟的性能、耐用性和广泛的临床应用，它们在市场份额中占据了重要地位。同时，生物可降解支架正在迅速获得关注，吸引了医疗从业者和患者的目光，这得益于其促进自然愈合过程的创新设计。 支架类型：金属（主流）与可生物降解（新兴） 金属支架以其坚固的结构为特征，确保在血管系统内的耐用性和可靠性。它们有多种设计，便于在治疗不同病症时的灵活应用。其现有的市场渗透率得到了广泛临床数据的支持，展示了其在预防再狭窄方面的有效性。相反，生物可降解支架代表了一种新兴技术，通过在完成其功能后逐渐溶解，提供独特的优势。这一特性最小化了长期并发症，并与当代健康趋势相一致，倾向于更少侵入性的解决方案。其日益增长的采用受到材料科学持续进步和对个性化医疗日益重视的推动。 ### 按类型：药物洗脱支架（最大）与裸金属支架（增长最快） 外周支架市场目前在其主要细分市场中展现出多样化的份额分布：药物洗脱支架（DES）、裸金属支架（BMS）和覆盖支架。在这些支架中，药物洗脱支架占据了最大的份额，反映出其因药物涂层机制而被广泛采用和偏好的趋势，这有助于防止再狭窄。相反，裸金属支架已成为增长最快的细分市场，主要受到成本效益和在各种临床场景中广泛适用性的推动。这一动态导致了一个竞争激烈的市场格局，其中DES保持着显著的领先地位，但BMS正在迅速获得市场份额。 展望未来趋势，裸金属支架的增长受到越来越多需要快速和简单植入的程序的推动，而这些程序不涉及药物洗脱解决方案的复杂性。外周动脉疾病（PAD）的发病率上升以及对日益增长的老年人口进行干预的需求是推动这一细分市场向前发展的关键驱动因素。此外，技术进步和降低医疗成本的推动使临床医生在许多情况下考虑BMS作为一种可行且高效的选择，从而提升了其市场地位。 支架类型：药物洗脱支架（主导）与裸金属支架（新兴） 药物洗脱支架（DES）因其先进的技术在外周支架市场中确立了主导地位，该技术通过局部药物输送降低了再狭窄的风险。这些支架在复杂动脉疾病病例中越来越受到青睐，为患者提供了更好的长期结果。与此同时，裸金属支架（BMS）被视为一个快速获得关注的新兴细分市场，因其结构简单、成本低廉和手术要求最低。随着医疗系统关注成本效益和高效的患者管理，BMS在常规应用中具有吸引力。这两种支架类型各自发挥着不同的作用，DES适用于高复杂度的手术，而BMS则针对更广泛的使用，反映了在实现最佳患者护理方面的平衡方法。 ### 按应用：外周动脉疾病（最大）与胆道阻塞（增长最快） 在外周支架市场中，应用细分显示出显著的多样性，外周动脉疾病（PAD）因其广泛的流行性和干预的必要性而在市场份额中占据主导地位。紧随其后的是冠状动脉疾病，已建立了显著的市场存在，而胆道和输尿管梗阻正在获得关注，但目前所占份额较小。应用的变化反映了患者在获得足够血管治疗时面临的独特挑战和需求。 外周动脉疾病（显性）与胆道梗阻（新兴） 外周动脉疾病（PAD）作为外周支架市场的主导力量，得益于其高患者发生率和对缓解腿部血流问题的治疗选择的强劲需求。使用支架有效治疗PAD增强了其市场地位。相比之下，胆道梗阻代表了一个新兴细分市场，受到对支架技术的认识提高和技术进步的推动。尽管目前规模较小，但其增长轨迹陡峭，受到胆道疾病发生率上升和患者转诊介入程序的相应激增的推动。 ### 按最终用途：医院（最大）与专科诊所（增长最快） 在外周支架市场中，医院占据了终端使用细分市场的最大份额。这种主导地位源于它们丰富的资源、先进的技术和能够处理复杂程序的全面患者护理设施。医院通常在支架手术的数量上贡献显著，因为它们通常配备了进行高复杂度心血管干预所需的专业团队和基础设施。另一方面，虽然门诊手术中心的市场份额较小，但由于它们以更高效和更具成本效益的方式提供专业服务，正在迅速增长。 该细分市场的增长趋势受到患者意识提高、技术进步以及向门诊护理模式转变的推动。随着越来越多的外周血管手术从住院转向门诊，门诊手术中心正在经历快速增长。专科诊所也作为关键参与者出现，受益于其专注的服务和个性化护理，吸引寻求微创选项和更短恢复时间的患者。 医院（主导）与专科诊所（新兴） 医院在外周支架市场的主导地位归因于其全面的能力，能够满足广泛的心血管干预需求。他们提供从诊断到手术程序的全方位服务，配备尖端技术和专业的医疗团队。相比之下，专科诊所作为新兴参与者正在获得动力，专门针对血管手术。这些诊所通常专注于提供具有成本效益的护理和更短的等待时间，吸引越来越多的倾向于选择微创治疗的知情患者。个性化医疗的日益增长趋势正在推动专科诊所完善其服务并提升患者体验，使其在更广泛的医疗环境中成为有吸引力的替代选择。 ## Regional Market Share Analysis ### 北美：创新的市场领导者 北美是外周支架最大的市场，占全球市场份额的约45%。该地区的增长受到先进医疗基础设施、外周动脉疾病日益普遍以及对创新的强烈关注的推动。来自FDA等机构的监管支持进一步促进了市场扩展，确保了尖端技术和治疗的可用性。美国是该市场的主要贡献者，主要参与者如美敦力、波士顿科学和雅培在竞争格局中处于领先地位。这些主要公司的存在为研究和开发创造了一个强大的环境，增强了产品供应。此外，日益增长的老年人口和不断上升的医疗支出预计将在未来几年内维持对外周支架的需求。 ### 欧洲：新兴市场动态 欧洲在外周支架市场上正经历显著增长，约占全球市场份额的30%。该地区受益于完善的医疗系统、对外周动脉疾病的日益关注以及支持性的监管框架。德国和法国等国处于前沿，通过先进的医疗技术和创新的治疗选择推动需求。德国在市场中处于领先地位，得益于B. Braun和Terumo等主要参与者的强大存在。竞争格局的特点是公司之间的合作与伙伴关系，以增强产品供应。此外，欧盟的医疗器械法规确保了安全性和有效性的高标准，进一步提升了市场信心和采用率。 ### 亚太地区：快速增长的市场 亚太地区正在成为外周支架市场的重要参与者，约占全球市场份额的20%。该地区的增长受到医疗投资增加、心血管疾病日益普遍以及老年人口增长的推动。日本和中国等国在这一增长中处于领先地位，得益于政府旨在改善医疗服务和质量的举措。日本凭借其先进的医疗基础设施和对研究与开发的强烈关注而脱颖而出。Terumo和Cook Medical等主要参与者正在积极扩大在该地区的影响力。竞争格局正在演变，地方制造商也开始进入市场，增强了竞争并推动了产品创新。 ### 中东和非洲：未开发的市场潜力 中东和非洲地区在外周支架市场上逐渐崭露头角，约占全球市场份额的5%。增长受到医疗投资增加、对心血管疾病的认识提高以及医疗基础设施改善的推动。南非和阿联酋等国在这一领域处于领先地位，政府采取措施以增强医疗服务和获取先进医疗技术的能力。南非是该市场的关键参与者，越来越多的医疗设施采用先进的支架技术。竞争格局的特点是本地和国际参与者的混合，包括强生和AngioDynamics。随着医疗系统的不断发展，对外周支架的需求预计将上升，为市场扩展提供了重大机会。 ## Competitive Benchmarking 外周支架市场的特点是动态的竞争格局，受到技术进步、外周动脉疾病的日益普遍以及日益增长的老龄化人口的推动。主要参与者如[美敦力](https://www.medtronic.com/en-us/healthcare-professionals/products/cardiovascular/peripheral-biliary-stents.html)（美国）、波士顿科学（美国）和雅培（美国）处于前沿，各自采取不同的策略来增强其市场定位。美敦力（美国）专注于通过开发下一代支架技术来推动创新，而波士顿科学（美国）则强调战略合作伙伴关系以扩展其产品供应。雅培（美国）利用其强大的研发能力推出尖端解决方案，从而塑造一个优先考虑技术优势和患者结果的竞争环境。 在商业策略方面，公司越来越多地本地化制造，以降低成本并提高供应链效率。市场看起来适度分散，几家主要参与者在各个细分市场施加影响。这种分散使得小型参与者能够蓬勃发展，而大型公司则通过并购巩固其地位，从而加剧竞争。 在2025年8月，美敦力（美国）宣布推出其最新的外周支架，该支架采用先进的生物可吸收技术，旨在改善患者的恢复时间。这一战略举措不仅强化了美敦力对创新的承诺，还使公司能够通过满足对微创解决方案日益增长的需求来占据更大的市场份额。该产品的推出可能会增强美敦力的竞争优势，特别是在外周动脉疾病发病率较高的地区。 在2025年9月，波士顿科学（美国）与一家领先的数字健康公司达成合作，将人工智能驱动的分析集成到其支架监测系统中。这一合作关系表明了行业内数字化转型的更广泛趋势，旨在为医疗专业人员提供实时数据，以优化患者护理。通过拥抱数字解决方案，波士顿科学（美国）不仅增强了其产品供应，还将自己定位为技术与医疗保健整合的领导者。 在2025年7月，雅培（美国）完成了对一家专注于创新支架输送系统的小型公司的收购。这一收购在战略上具有重要意义，因为它扩展了雅培的产品组合，并增强了其提供先进支架技术的能力。这一举措反映了市场内整合的日益增长趋势，因为公司寻求通过战略收购来增强其技术能力和市场覆盖。 截至2025年10月，外周支架市场正在见证强调数字化、可持续性和人工智能整合的趋势。战略联盟越来越多地塑造竞争格局，使公司能够利用互补优势并增强其产品供应。展望未来，竞争差异化可能会从传统的基于价格的竞争演变为关注创新、技术进步和供应链可靠性，因为公司努力满足快速变化的医疗环境的需求。 ## Recent News & Developments - **2024年第二季度：波士顿科学公司宣布Ranger™药物涂层气球获得FDA批准，用于外周动脉疾病** 波士顿科学公司获得FDA批准，其Ranger™药物涂层气球旨在治疗患有股浅动脉和腘动脉外周动脉疾病的患者。该批准扩展了公司在外周血管介入设备方面的产品组合。 - **2024年第二季度：美敦力获得Onyx Frontier™药物洗脱支架系统的CE标志** 美敦力宣布已获得Onyx Frontier™药物洗脱支架系统的CE标志批准，该系统适用于外周血管介入。该批准允许美敦力在欧盟市场销售该设备。 - **2024年第二季度：BD在欧洲推出新的外周血管支架系统** BD宣布在部分欧洲市场商业推出其新的外周血管支架系统。该设备旨在改善患有外周动脉疾病患者的血管通畅性。 - **2024年第三季度：雅培获得Esprit BTK依维莫司洗脱生物可吸收支架系统的FDA批准** 雅培获得FDA批准，其Esprit BTK依维莫司洗脱生物可吸收支架系统，旨在治疗膝下外周动脉疾病。这标志着生物可吸收支架技术在美国的一个重要监管里程碑。 - **2024年第三季度：Terumo在日本推出Ultimaster Tansei™药物洗脱支架，用于外周动脉疾病** Terumo宣布在日本推出其Ultimaster Tansei™药物洗脱支架，扩展其在日本市场的外周血管产品系列。 - **2024年第四季度：Cook Medical宣布在美国推出Zilver® PTX®药物洗脱外周支架市场** Cook Medical在美国推出其Zilver® PTX®药物洗脱外周支架市场，继最近获得FDA批准后。该支架适用于治疗股腘动脉的外周动脉疾病。 - **2024年第四季度：Cordis宣布与MedAlliance建立战略合作伙伴关系，分销外周药物洗脱支架** Cordis与MedAlliance建立战略合作伙伴关系，在部分全球市场分销MedAlliance的外周药物洗脱支架产品，旨在扩大对先进支架技术的获取。 - **2025年第一季度：Biotronik获得Pulsar-18 T3外周自扩张支架系统的CE标志** Biotronik宣布获得Pulsar-18 T3外周自扩张支架系统的CE标志批准，使其在欧盟的商业化成为可能，用于治疗外周动脉疾病。 - **2025年第一季度：波士顿科学在亚太地区推出Eluvia™药物洗脱血管支架** 波士顿科学在亚太地区推出其Eluvia™药物洗脱血管支架，扩大其在外周支架市场的全球影响力。 - **2025年第二季度：美敦力宣布IN.PACT™ AV药物涂层气球获得FDA批准，用于外周血管疾病** 美敦力获得FDA批准，其IN.PACT™ AV药物涂层气球，旨在治疗血液透析患者的动静脉瘘外周血管疾病。 - **2025年第二季度：雅培在欧洲推出新一代Xience Skypoint™支架，用于外周动脉疾病** 雅培宣布在欧洲推出其新一代Xience Skypoint™支架，旨在治疗外周动脉疾病，继获得CE标志批准后。 - **2025年第二季度：Terumo在越南开设新的外周血管设备制造厂** Terumo公司在越南开设新的外周血管设备制造厂，旨在满足日益增长的全球需求。 ## Report Scope | 2024年市场规模 | 114.3（十亿美元） | | --- | --- | | 2025年市场规模 | 117.9（十亿美元） | | 2035年市场规模 | 160.7（十亿美元） | | 年复合增长率（CAGR） | 3.14%（2024 - 2035） | | 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 | | 基准年 | 2024 | | 市场预测期 | 2025 - 2035 | | 历史数据 | 2019 - 2024 | | 市场预测单位 | 十亿美元 | | 主要公司简介 | 市场分析进行中 | | 覆盖的细分市场 | 市场细分分析进行中 | | 主要市场机会 | 生物可降解材料的进步提高了外周支架市场的安全性和有效性。 | | 主要市场动态 | 技术进步和监管变化推动外周支架市场的创新和竞争。 | | 覆盖的国家 | 北美、欧洲、亚太、南美、中东和非洲 | ## Frequently Asked Questions **Q: 到2035年，外周支架市场的预计市场估值是多少？** A: 外周支架市场预计到2035年将达到160.7亿美元的估值。 **Q: 2024年外周支架市场的市场估值是多少？** A: 在2024年，外周支架市场的价值为114.3亿美元。 **Q: 在2025年至2035年的预测期内，外周支架市场的预期CAGR是多少？** A: 在2025年至2035年的预测期内，外周支架市场的预期年复合增长率（CAGR）为3.14%。 **Q: 在外周支架市场中，哪些公司被视为关键参与者？** A: 外周支架市场的主要参与者包括美敦力、波士顿科学、雅培、B. Braun、Terumo、Cook Medical、Cardinal Health、强生和AngioDynamics。 **Q: 到2035年，金属支架的预计收入是多少？** A: 预计金属支架的收入将从2024年的50亿美元增长到2035年的70亿美元。 **Q: 药物洗脱支架与裸金属支架在市场估值方面如何比较？** A: 药物洗脱支架预计将从2024年的45.7亿美元增长到2035年的65亿美元，而裸金属支架预计将从34.3亿美元增长到45亿美元。 **Q: 到2035年，外周动脉疾病应用的预期市场规模是多少？** A: 外周动脉疾病应用的市场规模预计将从2024年的34.3亿美元增长到2035年的45.7亿美元。 **Q: 在外周支架市场中，预计哪个细分市场将实现最高的收入增长？** A: 药物洗脱支架的市场预计将实现最高的收入增长，预计到2035年将达到65亿美元。 **Q: 到2035年，门诊手术中心的预期市场规模是多少？** A: 预计到2035年，门诊手术中心的市场规模将从2024年的32.5亿美元增加到45亿美元。 **Q: 到2035年，混合支架市场预计将如何增长？** A: 混合支架市场预计将从2024年的19.3亿美元增长到2035年的25.7亿美元。 --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/peripheral-stent-market-39271*